Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Keefe

Showing results (171-180 of 188) with videos related to

Pageof 19
Sort By:
BMC Health Services Research|May 17, 2022
Influences of post-implementation factors on the sustainability, sustainment, and intra-organizational spread of complex interventionsYuting Song, Lauren MacEachern, Malcolm B Doupe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 studyA R Hansen, C Massard, P A Ott, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Cancer Chemotherapy and Pharmacology|May 10, 2023
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapySamantha K Korver, Joanne M Bowen, Rachel J Gibson, et al.
The British Journal of Dermatology|May 10, 2002
Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trialM Bhushan, T O Bleiker, A E Ballsdon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and TreatmentJeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatmentJeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2023
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826Bradley J Monk, Nicoletta Colombo, Krishnansu S Tewari, et al.
Implementation Science : IS|February 5, 2017
Pathways for best practice diffusion: the structure of informal relationships in Canada's long-term care sectorJames W Dearing, Amanda M Beacom, Stephanie A Chamberlain, et al.
The New England Journal of Medicine|September 17, 2021
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical CancerNicoletta Colombo, Coraline Dubot, Domenica Lorusso, et al.
Pageof 19

Showing results (171-180 of 188) with videos related to

Sort By:
Pageof 19
BMC Health Services Research|May 17, 2022
Influences of post-implementation factors on the sustainability, sustainment, and intra-organizational spread of complex interventionsYuting Song, Lauren MacEachern, Malcolm B Doupe, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 12, 2018
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 studyA R Hansen, C Massard, P A Ott, et al.
The Lancet. Oncology|October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Cancer Chemotherapy and Pharmacology|May 10, 2023
Advanced statistics identification of participant and treatment predictors associated with severe adverse effects induced by fluoropyrimidine-based chemotherapySamantha K Korver, Joanne M Bowen, Rachel J Gibson, et al.
The British Journal of Dermatology|May 10, 2002
Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trialM Bhushan, T O Bleiker, A E Ballsdon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2016
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and TreatmentJeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2014
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatmentJeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2023
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826Bradley J Monk, Nicoletta Colombo, Krishnansu S Tewari, et al.
Implementation Science : IS|February 5, 2017
Pathways for best practice diffusion: the structure of informal relationships in Canada's long-term care sectorJames W Dearing, Amanda M Beacom, Stephanie A Chamberlain, et al.
The New England Journal of Medicine|September 17, 2021
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical CancerNicoletta Colombo, Coraline Dubot, Domenica Lorusso, et al.
Pageof 19